The public procurement is divided into 6 parts and the tenderer may submit a tender for one or more lots. Tenders must comply with the technical specifications (Annex 1 to RHAD).

Trastuzumab powder for concentrate for solution for infusion, pharmaceutical form 150mg or 150mg and 420mg, biosimilar or biooriginal. The corresponding expected volumes and conditions are given in the technical specifications of the public procurement.

Trastuzumab subcutaneous solution for injection, dosage form 600mg. The corresponding expected volumes and conditions are given in the technical specifications of the public procurement.

Rituximab concentrate for solution for infusion, dosage form 500mg, biooriginal. The corresponding expected volumes and conditions are given in the technical specifications of the public procurement.

Rituximab concentrate for solution for infusion, dosage forms 500mg and 100mg, biosimilar or biooriginal. Corresponding expected volumes in the tender specifications for both pharmaceutical forms.

Rituximab subcutaneous solution for injection, dosage forms 1400mg and 1600mg. The corresponding expected volumes and conditions are given in the technical specifications of the public procurement.

Infliximab powder for concentrate for solution for infusion, pharmaceutical form 100mg, biosimilar or biooriginal. The corresponding expected volumes and conditions are given in the technical specifications of the public procurement.